Announced
Synopsis
OmnigenicsAI, a precision medicine company, agreed to go public via SPAC merger with APx Acquisition, a publicly traded special purpose acquisition company, in a $340m deal. "OmnigenicsAI is pioneering a new category of healthcare that integrates the groundbreaking potential of artificial intelligence with today´s access to vast amounts of genomic data, to provide personalized insights that empower individuals to make informed health decisions throughout their lives," Mark Ramondt, OmnigenicsAI CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.